Patte 2007.

Methods	Multicentre, 4‐arm study.
Participants	Eligibility: non‐immune compromised; < 18 years or 21 years with newly diagnosed B‐cell lymphoma. Tumour staging: non‐resected stages I to III & stage IV, CNS negative (St Jude/ Murphy classification). 762 eligible; 657 randomised; results based on 637.
Interventions	A factorial design between 4 arms, 2 receiving half‐dose of C in the second induction course with C, O, P, AD (doxorubicon), MTX (1A versus 1B) and 2 not receiving the maintenance course M1 (2A versus. 2B).
Outcomes	Event‐free survival. Overall survival. Failure‐free survival.
Notes	All participants had a standard pre‐randomisation phase and received COP and COPADM1. Median follow up period 54 months.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Said to be done at national group level.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Stated as an open trial.
Incomplete outcome data (attrition bias) All outcomes	Low risk	657 randomised but 20 excluded post randomisation due to wrong classification and lack of clinical data.